Creative Medical Technology Holdings Inc. announced positive interim 180-day follow-up data from its FDA-cleared ADAPT clinical trial evaluating CELZ-201 (Olastrocel), a perinatal tissue-derived cell therapy for chronic lower back pain associated with degenerative disc disease. The interim results, which have already been presented, demonstrated statistically significant improvements in functional disability and pain reduction, with approximately 79% of patients achieving clinically meaningful improvement in both areas. An independent Data Safety Monitoring Board review confirmed no serious adverse events and no treatment-related safety signals. The company indicated plans for late-stage regulatory engagement, strategic partnership discussions, and commercialization pending final data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Creative Medical Technology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9624319-en) on January 13, 2026, and is solely responsible for the information contained therein.